Research programme: Antibody drug conjugate therapeutics- NBE Therapeutics/SOTIO

Drug Profile

Research programme: Antibody drug conjugate therapeutics- NBE Therapeutics/SOTIO

Alternative Names: CD19 targeting antibody drug conjugates- NBE Therapeutics; CD30 targeting antibody drug conjugates- NBE Therapeutics; HER2 targeting antibody drug conjugates- NBE Therapeutics; NBE 001- NBE Therapeutics; NBE 002- NBE Therapeutics; PNU-159682-brentuximab antibody drug conjugate - NBE Therapeutics; PNU-159682-cAC10 antibody drug conjugate - NBE Therapeutics; PNU-159682-trastuzumab antibody drug conjugate - NBE Therapeutics; SO N102

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NBE-Therapeutics
  • Developer NBE-Therapeutics; SOTIO
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaplastic large cell lymphoma; B cell lymphoma; Breast cancer; Cancer; Hodgkin's disease; Leukaemia; Lung cancer; Multiple myeloma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Research Pancreatic cancer; Renal cell carcinoma

Most Recent Events

  • 29 May 2018 Preclinical trials in Cancer in Czech Republic (Parenteral) prior to May 2018 (SOTIO pipeline, May 2018)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017) (Parenteral)
  • 29 Aug 2016 Antibody drug conjugate targeting CD19 out-licensed to an undisclosed organisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top